Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Alkermes (ALKS) Stock Price
News headlines about Alkermes (NASDAQ:ALKS) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Alkermes earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 47.6260047757899 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- Catalyst-Rich Months Ahead For The Alkermes Pipeline (seekingalpha.com)
- Analysts Expect Alkermes Plc (ALKS) Will Announce Quarterly Sales of $235.77 Million (americanbankingnews.com)
- Scroll Latest Stock’s Report: Alkermes plc (ALKS), Berkshire Hills Bancorp (BHLB) (newsregistrar.com)
- Be unsteadying Stocks: Public Joint-Stock Company Mobile TeleSystems (NYSE:MBT), Alkermes plc (NASDAQ:ALKS … (thestreetpoint.com)
- Notable Tuesday Option Activity: ALKS, NCLH, EHTH (nasdaq.com)
ALKS stock opened at $44.53 on Monday. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.92 and a quick ratio of 2.62. Alkermes has a 12 month low of $39.54 and a 12 month high of $71.22. The company has a market capitalization of $6.84 billion, a PE ratio of -120.35 and a beta of 1.73.
A number of research firms have recently commented on ALKS. ValuEngine upgraded shares of Alkermes from a “strong sell” rating to a “sell” rating in a research report on Thursday, May 31st. Zacks Investment Research lowered shares of Alkermes from a “buy” rating to a “hold” rating in a research report on Monday, May 28th. Citigroup upgraded shares of Alkermes from a “neutral” rating to a “buy” rating and set a $62.00 price objective for the company in a research report on Wednesday, May 16th. B. Riley began coverage on shares of Alkermes in a research report on Wednesday, June 6th. They issued a “buy” rating and a $60.00 price objective for the company. Finally, BidaskClub upgraded shares of Alkermes from a “hold” rating to a “buy” rating in a research report on Wednesday, June 13th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $55.71.
In related news, SVP Michael J. Landine sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 24th. The shares were sold at an average price of $45.22, for a total value of $904,400.00. Following the sale, the senior vice president now directly owns 192,644 shares of the company’s stock, valued at $8,711,361.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP James M. Frates sold 16,842 shares of the firm’s stock in a transaction that occurred on Tuesday, June 12th. The shares were sold at an average price of $50.00, for a total transaction of $842,100.00. The disclosure for this sale can be found here. Insiders sold 79,842 shares of company stock worth $3,667,580 over the last ninety days. 5.51% of the stock is currently owned by insiders.
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes.
Featured Article: Stock Symbol
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.